Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

Cyclooxygenase2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers. Here, the potential utility of selective COX-2 inhibitors in the prevention and treatment of cancer is considered. The mechanisms by which COX-2 levels increase in cancers, key data that indicate a causal link between increased COX-2 activity and tumorigenesis, and possible mechanisms of action of COX-2 are discussed. In a proof-of-principle clinical trial, treatment with the selective COX-2 inhibitor celecoxib reduced the number of colorectal polyps in patients with familial adenomatous polyposis. Selective COX-2 inhibitors appear to be sufficiently safe to permit large-scale clinical testing and numerous clinical trials are currently under way to determine whether selective inhibitors of COX-2 are effective in the prevention and treatment of cancer.

[1]  F. Robertson,et al.  Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. , 1999, Cancer letters.

[2]  E. Hawk,et al.  Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. , 2000, Cancer research.

[3]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[4]  D. Dixon,et al.  Transforming Growth Factor-β1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA* , 2000, The Journal of Biological Chemistry.

[5]  D. A. Dixon,et al.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. , 2001, The Journal of clinical investigation.

[6]  J. Morrow,et al.  Regulation of Constitutive Cyclooxygenase-2 Expression in Colon Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[7]  F. Marks,et al.  Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[9]  J. Bolognese,et al.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.

[10]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[11]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[12]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[13]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[14]  R. Langenbach,et al.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.

[15]  A. Castonguay,et al.  Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. , 1998, Cancer research.

[16]  M. Sliwkowski,et al.  Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. , 2001, Gastroenterology.

[17]  C. Gomer,et al.  Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. , 2002, Cancer research.

[18]  A. Sorokin,et al.  Regulation of MDR-1 (P-glycoprotein) by Cyclooxygenase-2* , 2002, The Journal of Biological Chemistry.

[19]  Fan Zhang,et al.  Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-2* , 1998, The Journal of Biological Chemistry.

[20]  Y. Konishi,et al.  Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. , 2001, Cancer research.

[21]  Thomas M. McIntyre,et al.  Post-transcriptional Control of Cyclooxygenase-2 Gene Expression , 2000, The Journal of Biological Chemistry.

[22]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[23]  D. Dunson,et al.  Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. , 2002, Cancer research.

[24]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[25]  T. Tsuruo,et al.  Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522 , 1999, British Journal of Cancer.

[26]  P. Tofilon,et al.  Enhancement of Tumor Response to γ-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme , 1999 .

[27]  Li Zhu,et al.  Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.

[28]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[29]  B. Levine,et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. , 2002, Cancer research.

[30]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[31]  I. Gibbs,et al.  Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. , 2000, International journal of radiation oncology, biology, physics.

[32]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[33]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis , 1999, Molecular carcinogenesis.

[34]  V. Steele,et al.  Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. , 2000, Cancer research.

[35]  S. Ghosh,et al.  Transcriptional Activation of the Cyclooxygenase-2 Gene in Endotoxin-treated RAW 264.7 Macrophages* , 2000, The Journal of Biological Chemistry.

[36]  W. White,et al.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. , 2002, The American journal of cardiology.

[37]  Kenneth K Wang,et al.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. , 2002, Gastroenterology.

[38]  Y. Bang,et al.  Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. , 2001, Cancer research.

[39]  K. Subbaramaiah,et al.  Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. , 2001, The Journal of biological chemistry.

[40]  H. Sheng,et al.  Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. , 2000, Cancer research.

[41]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[42]  H. Sheng,et al.  Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. , 2000, Neoplasia.

[43]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[44]  A. Dannenberg,et al.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. , 2002, Neoplasia.

[45]  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000 .

[46]  K. Matsuo,et al.  Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  C. Mendelson,et al.  Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.

[48]  R. Langenbach,et al.  Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts , 1999, The Journal of experimental medicine.

[49]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[50]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[51]  P. Cole,et al.  Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. , 2002, Cancer research.

[52]  Aubrey R. Morrison,et al.  The 3′-Untranslated Region of Murine Cyclooxygenase-2 Contains Multiple Regulatory Elements That Alter Message Stability and Translational Efficiency* , 2001, The Journal of Biological Chemistry.

[53]  L. Norton,et al.  Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2 , 2000, The Journal of Biological Chemistry.

[54]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[55]  N. Altorki,et al.  Inhibition of Cyclooxygenase-2 Gene Expression by p53* , 1999, The Journal of Biological Chemistry.

[56]  F. Chan,et al.  Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer , 2001, British Journal of Cancer.

[57]  K. Subbaramaiah,et al.  Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. , 1996, Cancer research.

[58]  P. Taylor,et al.  Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? , 2001, Anticancer research.

[59]  K. Kawakami,et al.  A Selective Cyclooxygenase‐2 Inhibitor Suppresses Tumor Growth in Nude Mouse Xenografted with Human Head and Neck Squamous Carcinoma Cells , 1999, Japanese journal of cancer research : Gann.

[60]  K. Seibert,et al.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.

[61]  B. Levin,et al.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis , 2002, Gut.